Highlights of ASCO

Frank Griesinger
Additional contact information
Frank Griesinger: Department of Hematology and Oncology, University Internal Medicine-Oncology, Germany

International Journal of Pulmonary & Respiratory Sciences, 2019, vol. 4, issue 2, 38-42

Abstract: The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.

Keywords: uniper publishers:International Journal of Pulmonary; Journal of Pulmonary Sciences; Journal of Pulmonary & Respiratory Sciences; Pulmonary & Respiratory Sciences; pulmonary & respiratory medicine open access journals; pulmonary & respiratory medicine impact factor journals; pulmonary & respiratory medicine peer review journals; chronic obstructive pulmonary disease; pulmonary arterial hypertension impact factor journals; pulmonary aspergillosis high impact factor journals (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ijoprs/pdf/IJOPRS.MS.ID.555634.pdf (application/pdf)
https://juniperpublishers.com/ijoprs/IJOPRS.MS.ID.555634.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:ijoprs:v:4:y:2019:i:2:p:38-42

DOI: 10.19080/IJOPRS.2019.04.555634

Access Statistics for this article

International Journal of Pulmonary & Respiratory Sciences is currently edited by Sophia Mathis

More articles in International Journal of Pulmonary & Respiratory Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().